Abstract 433P
Background
An estimated 70-80% of malignancies need multimodal treatment, which includes surgery, radiation, and chemotherapy. Radiation oncology is particularly vulnerable to regional disparities in access to care due to the unique nature of its treatments.It is vital to define geographic and demographic access to radiotherapy in order to improve patient access to clinical care.This first of its kind study aimed at quantifying the available radiation oncology resources across all Asian counties.
Methods
The availability of Teletherapy and Brachytherapy resources of all Asian Countries was obtained from IAEA-DIRAC. The population o was estimated using World Bank Population Estimates. The incidence of cancers was obtained from Globocan Reports.Available number of treatment units were compared with that of the population, overall cancer incidence and five most common cancers among countries across Asia. Total EBRT treatment capacity was estimated by multiplying the number of units per country with 240 working days. Assuming that 50 patients would be treated per day, a proportional treatment space of 15% was estimated for Breast and lung cancers and, 10% each for stomach, cervical and oesophageal cancers. Therefore, feasible fractions were estimated as: number of EBRT units per country × 240 × (0.15 or 0.10) × 50. Number of excess or deficit fractions were calculated, and the total number of extra machines required was arrived at.
Results
Number of teletherapy units varied from 1 to 1825 across countries. Yemen had the least number of teletherapy units per million population (0.03) whereas Japan had the highest (8.66). Brunei had 1 teletherapy machine per 493 cancer cases whereas North Korea had 1 machine per 19218 cases. Qatar had 1 brachytherapy machine for 1482 cancer cases and Taiwan had 1 Brachytherapy machine for 55483 cancer cases.41 countries had a deficit in number of teletherapy machines with respect to breast cancer. Similarly, 33, 28, 32 and 18 countries had a deficit with respect to lung, stomach, cervical and oesophageal cancers respectively.
Conclusions
The study identified deficits of radiotherapy units in terms of geographic and demographic aspect across Asian countries and provides a roadmap for development of radiation oncology infrastructure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abhishek Krishna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06